Opportunities
Search

This notice of funding opportunity (NOFO) invites applications designed to examine the efficacy and clinical effectiveness of multimodality digital health technology approaches to the remote management of diabetes.

Expected Impact:The developed solutions should demonstrate their potential in concrete terms through the execution of a first roll-out stage during the project life-cycle, with a strong uptake strategy guiding their future adoption after the end of the project. The sustainability of the results and their continued benefits to users is a key ambition of this call for proposals.The project is furthermore expected to make a strong impact for the wider ecosystem of European decentralised social media. The insights gained on youth needs and desires on mental-health and inclusivity friendly social media should benefit the wider community of stakeholders in this space, and wherever possible developed technology should contribute to the software stacks of the ActivityPub and ATProtocol communities.Finally, the project should generate insights on the opportunities and challenges for decentralised...

Expected Outcome:This call for proposals supports implementation of the following key principles of the European Pillar of Social Rights: (3) equal opportunities; (5) secure and adaptable employment; (6) wages; (7)information about employment conditions and protection in case of dismissals; (8) social dialogue and involvement of workers; (10) healthy, safe and well –adapted work environment and data protection. The general objective of this call for proposals is therefore contributing to the implementation of the key principles of the pillar in the area of posting of workers. The specific objectives are the following:a) To promote transnational cooperation among public authorities and stakeholders, including the promotion of the use of IMI and sharing experiences and best practices in this respect;b) To increase the accessibility, transparency and quality of the information concerning th...

HBCU-UP provides awardsto strengthen STEM undergraduate education and research at Historically Black Colleges and Universities (HBCUs).Support is available through thefollowing tracks: Targeted Infusion Projects (TIP), which provide support to achieve a short-term, well-defined goal for enhancing and innovating undergraduate STEM education at an HBCU. Research on Broadening Participation in STEMprojects (BPR), which provide support for researchthat seeks to create and study new theory-driven models and innovations related to the participation and success of underrepresented groups in STEM undergraduate education, especially African Americans. Research Initiation Awards (RIA), which provide support for STEM faculty with no prior or recent research funding to pursue research at the home institution, another research-intensive institution, an NSF-funded research center, or a national laboratory. Implementation Projects (IMP), which provide support to design, implement, study, and assess comprehensive institutional efforts for increasing the number of students receiving undergraduate degrees in STEM and enhancing their preparation by strengthening STEM education and research. Broadening Participation Research Centers (BPRC),which provide support to create centers that conduct research on STEM education and broadening participation and build the intellectual infrastructure to facilitate the creation, integration, and transfer of new knowledge. Other Funding Opportunities include EArly-Concept Grants for Exploratory Research (EAGER), Rapid Response Research (RAPID), conference, a...

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Focused Pilot Award supports the exploration and development of impactful and innovative concepts under a patient-centered focus area of pancreatic cancer research that could ultimately lead to major advancements that will have a profound effect on patients’ overall quality of life. The research this award supports should strive to produce robust preliminary data that can serve as a foundation for future clinical or real-world research application. Distinctive Features: This award mechanism allows, but does not require, preliminary data. Applications can support clinical research studies; however, this mechanism does not allow clinical trials. Preclinical animal studies do not meet the intent of this mechanism.

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award supports partnerships between clinicians, population scientists, applied scientists and/or basic scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. The partnership must include at least one member with expertise in pancreatic cancer research or pancreatic cancer patient care. All applications must address at least one of the FY26 PCARP Focus Areas. ·        This award mechanism requires preliminary data to support feasibility of the research hypothesis(es) and research approaches. However, these data do not necessarily need to originate from studies of pancreatic cancer. Applications can support retrospective tissue analysis, correlative studies and pilot clinical trials; however, this mechanism does not allow large-scale clinical trials. ·        The Translational Research Partnership Award requires two Principal Investigators (PIs) referred to as the Initiating PI and the Partnering PI. Only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Idea Development Award supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with pancreatic cancer. This award mechanism supports innovative ideas with the potential to yield impactful data and new avenues of investigation. All applications must address at least one of the FY26 PCARP Focus Areas. Distinctive Features: This award mechanism requires preliminary data relevant to the proposed project. Applications can support clinical research studies; however, this mechanism does not allow clinical trials. Partnering Principal Investigator (PI) Option for Early-Career Investigator: This funding mechanism offers a higher level of funding for applications that propose to partner an experienced PI (i.e., Initiating PI, who will serve as the mentor) with an Early-Career Investigator (i.e., Partnering PI) wishing to pursue a career in pancreatic cancer research. For this option, only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Expected Outcome: A consolidated reference on private situational data relevant for submarine-cable security A structured description of the main categories of private situational data and actors relevant for submarine-cable security, including their sensitivity profile, typical usage, and the key legal, regulatory and commercial constraints affecting possible access by Regional Cable Hubs. Interoperability and data fusion pathways for multi-source, multi-basin use Clear conclusions on the main interoperability and data fusion challenges and feasible solutions (e.g. common data models or ontologies, interoperability layers, translation and fusion layers), including indications on which approaches are realistically applicable across multiple providers and sea basins, and how they can remain extensible to accommodate new data sources and actors over time. A proof-of-concept demonstration s...

The Algebra and Number Theory program supports research in algebra, algebraic and arithmetic geometry, number theory, and representation theory. Conference proposals The Algebra and Number Theory program also provides support for conferences, workshops, summer/winter schools, and similar activities. Proposals should be submitted to PD 20-1264 using the "Conference" proposal type in research.gov. Proposals with budgets not exceeding $50,000, which in accordance with NSF policy can be reviewed internally, should be submitted: in May for events that will take place in January through April of the following year in October for events that will take place in May through December of the following year. In order to allow time for external review, proposals with budget requests exceeding $50,000 should be submitted nine to twelve months before the event is scheduled to take place.

Machine Learning and Artificial Intelligence (AI) are enabling extraordinary scientific breakthroughs in fields ranging from protein folding, natural language processing, drug synthesis, and recommender systems to the discovery of novel engineering materials and products. These achievements lie at the confluence of mathematics, statistics, engineering and computer science, yet a clear explanation of the remarkable power and also the limitations of such AI systems has eluded scientists from all disciplines. Critical foundational gaps remain that, if not properly addressed, will soon limit advances in machine learning, curbing progress in artificial intelligence. It appears increasingly unlikely that these critical gaps can be surmounted with increased computational power and experimentation alone. Deeper mathematical understanding is essential to ensuring that AI can be harnessed to meet the future needs of society and enable broad scientific discovery, while forestalling the unintended consequences of a disruptive technology. The National Science Foundation Directorates for Mathematical and Physical Sciences (MPS), Computer and Information Science and Engineering (CISE), Engineering (ENG), and Social, Behavioral and Economic Sciences (SBE) will jointly sponsor research collaborations consisting of mathematicians, statisticians, computer scientists, engineers, and social and behavioral scientists focused on the mathematical and theoretical foundations of AI. Research activities should focus on the most challenging mathematical and theoretical questions aimed at understanding...

This Notice of Funding Opportunity (NOFO) invites applications for a Research Coordinating Center (RCC) to participate in a consortium of clinical centers that will test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs. Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscriptsThe RCC will lead, manage, and harmonize efforts for the Consortium including 1) providing management and administrative support; 2) providing leadership and expertise on statistical design a...

This Notice of Funding Opportunity (NOFO) invites applications from clinical centers to participate in a consortium to test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs. Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscripts. This NOFO uses a cooperative agreement mechanism (U01) and runs in parallel with a companion NOFO (RFA-DK-27-136).

The overarching goal of this notice of funding opportunity (NOFO) and its companion opportunities is to establish the Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) Program to support development of innovative, reliable, cost-effective, and sustainable multimodal AI-based clinical decision support (CDS) tools. PRIMED-AI CDS tools are based on the integration of clinical imaging with other types of multimodal health data to enhance care for patients with a wide range of health conditions. The PRIMED-AI Program seeks to catalyze the adoption of AI-based CDS tools into clinical workflows to enable novel personalized medicine strategies that address significant health challenges. The purpose of this NOFO is to solicit applications for the design, development, and preliminary validation of robust frameworks for the application of multimodal-artificial intelligence (AI) models for clinical use. Frameworks developed through these awards would populate a "playbook", defined as a collection of actionable guidelines, standardized protocols, and/or standard operating procedures (SOPs) for reliable and effective development and deployment of multimodal AI tools. It is expected that the frameworks delineated in this playbook will directly address PRIMED-AI objectives and needs, while also remaining flexible enough to enable sufficient extensibility and interoperability for use across a broad spectrum of multimodal biomedical AI applications, both internal and external to the PRIMED-AI Program.

The purpose of this notice of funding opportunity (NOFO) is to elucidate the key components of the therapeutic effects of rapid-acting psychotropic interventional drugs (RAPIDs) by addressing the methodological challenges involved with these clinical trials. In addition, this NOFO seeks to advance understanding of how RAPIDs and adjunctive psychosocial interventions can be optimally delivered, monitored, and sustained over time to enhance effectiveness and generalizability. The NOFO will support studies designed to enhance the rigor of RAPID clinical trial design, which will ultimately increase the interpretability of the data and the generalizability of the results.

Expected Impact:Projects are expected to deliver results aligned with the expected results set out in this call topic and to evidence their contribution through dedicated KPIs defined in the proposal. Expected results include: • demonstrable and sustainable increase in production capacity for the targeted ammunition, bombs and missiles production lines, enabled by operational joint filling plants and production lines; • measurable reduction of production lead time from order/production decision to delivery in UA; • improved timely availability and supply of defence products for UA, including increased delivery reliability and readiness of production lines; • effective cross-border cooperation between UA and EU that enables production ramp-up, qualification, integration and sustainment. Proposals shall define, baseline and track KPIs such as: filling throughput (e.g., units/month or tonne...

Expected Impact:The results of the activities should contribute to support common procurement, leading to strengthening the cooperation among Member States and associated countries, as well as to greater interoperability. Furthermore, they should contribute to the building up of strategic stockpile of ammunition, missiles, including their components, or to the increase of existing ones, as well as to the development of low-cost unmanned systems for guided strikes adapted to modern warfare scenarios.Objective:This topic aims at actions supporting the common procurement of ammunition (including small arms ammunition, tank and anti-tank ammunitions, artillery ammunition, guided ammunitions), missiles (all types of missiles) and other explosive weapons (including hand grenade, land and naval mines, mortar, rockets, unmanned systems (aerial, ground, surface and underwater vehicles controlled...

Expected Impact:The results of the activities should contribute to support common procurement, leading to strengthening the cooperation among Member States and associated countries, as well as to greater interoperability. Furthermore, they should contribute to the replenishment of depleted stockpiles of counter-drone systems, to the increase of existing stockpiles or to establishment of defence industrial readiness pool, as well as to the development and reinforcement of counter-drone solutions as drones are being increasingly perceived as a pressing threat.Objective:This topic aims at actions supporting the common procurement of integrated systems (e.g. VSHORAD or SHORAD) or parts thereof (including sensors, kinetic or non-kinetic effectors - including direct energy weapons -, command and control solutions) to counter unmanned aerial, ground, surface or underwater vehicles, including th...

The Mathematical Biology Program supports research in all areas of mathematical sciences with relevance to the biological sciences. Successful proposals must demonstrate mathematical innovation, biological relevance and significance, and strong integration between mathematics and biology. Some projects of interest to the Mathematical Biology Program may include development of mathematical theories, methodologies, and tools traditionally seen in other disciplinary programs within the Division of Mathematical Sciences. In general, if a proposal is appropriate for review by more than one NSF program, it is advisable to contact the program officers handling each program to determine when and where the proposal should be submitted and to facilitate the review process. The Mathematical Biology Program regularly seeks joint reviews of proposals with programs in the Directorates of Biological Sciences and other relevant programs. Investigators are encouraged to discuss their project with program officers in relevant areas to determine whether it could be considered by more than one program. Research in Undergraduate Institutions (RUI) Investigators submitting an RUI proposal should read the RUI solicitation (link below), as the rules for proposal format may deviate from the Proposal & Award Policies & Procedures Guide (PAPPG). EAGER and RAPID Proposals Prior to submitting proposals for EArly-concept Grants for Exploratory Research (EAGER) or Rapid Response Research (RAPID), Investigators must contact the cognizant program directors. Requests for Award Supplements Principal Investig...

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This notice of funding opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO (PAR-23-286).

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply. This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFOs (PAR-23-287 or PAR-23-288).

The Research Experiences for Teachers (RET) in Engineering and Computer Science program supports authentic summer research experiences for K-14 educators to foster long-term collaborations between universities, community colleges, school districts, and industry partners. With this solicitation, the Directorates for Engineering (ENG) and Computer and Information Science and Engineering (CISE) focus on a reciprocal exchange of expertise between K-14 educators and research faculty and (when applicable) industry mentors. K-14 educators will enhance their scientific disciplinary knowledge in engineering or computer science and translate their research experiences into classroom activities and curricula to broaden their students’ awareness of and participation in computing and engineering pathways. At the same time, the hosting research faculty will deepen their understanding of classroom practices, current curricula, pedagogy, and K-14 educational environments.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and cli...

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this NOFO supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this NOFO supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population s...

Through this Notice of Funding Opportunity (NOFO) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of this NOFO is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" r "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer control and prevention. Research applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this NOFO encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Focused Program Award – Rare Melanomas, supports a multidisciplinary research program of at least two, but not more than three, distinct but complementary research projects addressing an overarching question relevant to rare melanomas. Distinctive Features: ·          *Updated for FY26* Investigators must include at least one rare melanoma survivor or patient advocate as part of the project team who will provide advice and consultation throughout planning, implementation, and results dissemination to maximize research impact. ·        This is a partnering mechanism, requiring an Initiating Principal Investigator (PI) and at least one, but not more than two, Partnering PIs, see Figure 1.                    Each named PI is expected to be a Project Leader for one of the proposed research projects. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). ·        After submitting the required pre-application, investigators must receive an invitation to submit a full application.                    Only the Initiating PI will submit a pre-application. All PIs must submit full applications. The Partnering PI(s)’s application is an abbreviated package specific to their proposed research project. ·        Clinical trials are allowed.